Clopidogrel vs. Aspirin for Primary Prevention in High-Risk Type 2 Diabetes

Clopidogrel vs. Aspirin for Primary Prevention in High-Risk Type 2 Diabetes

Atherosclerotic cardiovascular disease (ASCVD) poses a major threat to patients with type 2 diabetes, even without prior events. While aspirin is recommended for primary prevention in high-risk diabetic individuals, its benefits are offset by increased bleeding risks, particularly gastrointestinal (GI) bleeding. Clopidogrel, a P2Y12 inhibitor, has shown fewer GI events in secondary prevention trials, but its role in primary prevention remains unclear. This study aimed to compare the effectiveness and safety of clopidogrel versus aspirin in high- and very high-risk diabetic patients without ASCVD, using real-world data from the Korean National Health Insurance Service–National Sample Cohort (NHIS-NSC) from 2010-2019.

Efficacy of SGLT2 Inhibitors in HFpEF: A Systematic Review

Efficacy of SGLT2 Inhibitors in HFpEF: A Systematic Review

Heart failure with preserved ejection fraction (HFpEF) represents a significant clinical challenge due to limited effective pharmacological treatments. Sodium-glucose co-transporter 2 (SGLT2) inhibitors, such as empagliflozin and dapagliflozin, have emerged as a novel therapeutic approach. This systematic review synthesizes evidence from 10 randomized controlled trials (RCTs) involving diverse HFpEF patient populations, including those with comorbidities like diabetes and chronic obstructive pulmonary disease.

Semaglutide Linked to Neuromuscular Decline in Elderly T2DM Men

Semaglutide Linked to Neuromuscular Decline in Elderly T2DM Men

This prospective cohort study investigated the longitudinal impact of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), on sarcopenia indicators and biomarkers of neuromuscular junction (NMJ) stability and neuronal health in older men with type 2 diabetes mellitus (T2DM), compared to sitagliptin as a control. Older adults with T2DM are at elevated risk for sarcopenia, characterized by loss of muscle mass, strength, and function, which can exacerbate disability and reduce quality of life.

Empagliflozin Plus Metformin Enhances MASLD Outcomes in T2DM

Empagliflozin Plus Metformin Enhances MASLD Outcomes in T2DM

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease, particularly in patients with type 2 diabetes (T2D). The IMAGIN Study, a single-center prospective observational trial, investigated the impact of empagliflozin as an add-on to metformin versus metformin monotherapy on MASLD progression in SGLT2 inhibitor-naïve T2D patients with an estimated glomerular filtration rate (eGFR) ≥45 mL/min/1.73 m². The study aimed to assess changes in liver steatosis, fibrosis, and metabolic parameters, alongside exploring potential microRNA (miRNA) biomarkers for treatment response.

Dapagliflozin in Heart Failure with Improved Ejection Fraction

Dapagliflozin in Heart Failure with Improved Ejection Fraction

Heart failure with improved ejection fraction (HFimpEF) represents an understudied subgroup of heart failure patients who, despite LVEF improvement, face residual risks comparable to those with consistently higher LVEF (>40%). The prognostic implications of the degree of LVEF improvement and its impact on treatment response remain poorly understood. The DELIVER trial (NCT03619213) addresses this gap by evaluating dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with heart failure and LVEF >40%, including those with HFimpEF. This study explores whether the extent of LVEF improvement influences clinical outcomes and the therapeutic benefits of dapagliflozin.

Metformin’s Role in OA Pain and Weight Loss

Metformin’s Role in OA Pain and Weight Loss

A randomized, double-blind, placebo-controlled trial, published in JAMA, evaluated metformin’s efficacy for knee osteoarthritis (OA) in 108 overweight or obese adults (BMI ≥25 kg/m², mean age ~60 years) with symptomatic knee OA (Kellgren-Lawrence grade 2-3). Conducted over 18 months, patients received metformin (up to 2g daily) or placebo alongside standard care. Primary outcomes were changes in knee pain (WOMAC pain score, 0-20 scale) and cartilage volume loss (via MRI). Secondary outcomes included physical function (WOMAC function score), weight loss, and safety.